LifeSciences BC > News > Member Announcements

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

November 15, 2019
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 15, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will participate in the following investor conferences and present a company update when noted: Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day on Monday, November 18, 2019; … Continue reading Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

November 14, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Nov. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended September 30, 2019. “Following a productive quarter, we continue to believe that our cash position will provide the runway to enable us … Continue reading DelMar Pharmaceuticals Announces Fiscal First Quarter 2020 Financial Results and Recent Corporate Updates

Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results

November 13, 2019
Neoleukin Therapeutics, Inc.

SEATTLE, Wash., Nov. 13, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter ending September 30, 2019. “The past quarter has been transformational for Neoleukin across many fronts. We’ve acquired the capital for further development of our de … Continue reading Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results

InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

November 12, 2019
InMed Pharmaceuticals Inc.

Vancouver, BC – November 8, 2019 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September … Continue reading InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals to Present at the Cowen Conference

November 12, 2019

VANCOUVER, November 11, 2019 /CNW/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric Hsu, Senior Vice President, Preclinical Research and … Continue reading InMed Pharmaceuticals to Present at the Cowen Conference

SignalChem Initiates Phase 1 Clinical Trial for SLC-391 in Subjects with Solid Tumours

November 8, 2019
SignalChem Lifesciences Corp.

VANCOUVER, BRITISH COLUMBIA–(November 7, 2019) – SignalChem Lifesciences Corp. (“SLC”), a clinical stage biotech company, has dosed its first patient in a Phase 1 clinical trial studying the safety and tolerability of SLC-391, a potent and selective AXL inhibitor, at Princess Margaret Cancer Centre in Toronto, Ontario. The study marks a significant clinical milestone for … Continue reading SignalChem Initiates Phase 1 Clinical Trial for SLC-391 in Subjects with Solid Tumours

Dynacare Launches JOINTstat® Testing in Canada

November 6, 2019
Augurex

Augurex is pleased to announce the launch of JOINTstat (14-3-3ƞ) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians across Canada. JOINTstat, a biomarker blood test, provides … Continue reading Dynacare Launches JOINTstat® Testing in Canada

LifeSciences BC Attracts International Audience for Annual Investor’s Summit

November 6, 2019
LifeSciences BC

Vancouver, November 6, 2019 – Today, LifeSciences BC, a non-profit, industry association which supports and represents the life sciences community of British Columbia, and Lumira Ventures, a leading North American healthcare venture capital firm, will host the 4th annual LifeSciences BC’s Investor Summit in Vancouver, BC. The event brings together industry stakeholders from the healthcare … Continue reading LifeSciences BC Attracts International Audience for Annual Investor’s Summit

Back Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 6, 2019
Arbutus Biopharma Corp.

Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its third quarter 2019 financial results and provides a corporate update. “We remain committed to our mission of developing a portfolio of assets with differing mechanisms … Continue reading Back Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 5, 2019
Xenon Pharmaceuticals Inc.

In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy,  Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in  KCNQ2 (XEN496) and SCN8A (XEN901) Developmental and Epileptic Encephalopathies in 2020  XEN007 Phase 2 Proof-Of-Concept, Physician-Led Study Initiated in Pediatric Patients with   Treatment-Resistant Childhood Absence Epilepsy Conference Call at 4:30 pm … Continue reading Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update